Clinical trial · Observational
Current Status of BTKi Treatment for CLL/SLL in China
Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CLL/SLL | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BTK inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- BTK inhibitor treated
- description
- investigate the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, including the efficacy and safety, the drug swith between different BTKis，the BTKi based timed limited therapy, etc
- interventionNames
- Drug: BTK inhibitor
Primary outcomes (1)
- measure
- Patient characteristics of those receiving BTKi treatment
- timeFrame
- up to one year
- description
- Describe the patient characteristics of those receiving BTKi treatment, including age, gender, etc
Secondary outcomes (2)
- measure
- overall response rate
- timeFrame
- up to one year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years; * Patients with a confirmed diagnosis of CLL/SLL; * Received BTK inhibitor treatment between February 2023 and February 2024. Exclusion Criteria: * Patients with other types of lymphoma; * Cases deemed unsuitable for inclusion in this study by the investigators.
References
Publications (0)
Data not yet available